Merinopoulos, Ioannis; Gunawardena, Tharusha; Corballis, Natasha; Bhalraam, U; Reinhold, Johannes; Wickramarachchi, Upul; Maart, Clint; ... Eccleshall, Simon C; + view all Merinopoulos, Ioannis; Gunawardena, Tharusha; Corballis, Natasha; Bhalraam, U; Reinhold, Johannes; Wickramarachchi, Upul; Maart, Clint; Gilbert, Tim; Richardson, Paul; Sulfi, Sreekumar; Sarev, Toomas; Sawh, Chris; Wistow, Trevor; Ryding, Alisdair; Mohamed, Mohamed O; Perperoglou, Aris; Mamas, Mamas A; Vassiliou, Vassilios S; Eccleshall, Simon C; - view fewer (2023) Assessment of Paclitaxel Drug-Coated Balloon Only Angioplasty in STEMI. JACC: Cardiovascular Interventions , 16 (7) pp. 771-779. 10.1016/j.jcin.2023.01.380.

Preview

PDF Merinopoulos-JINT113022-2724DR.pdf - Accepted Version Download (296kB) | Preview

Abstract

Background: Primary percutaneous coronary intervention (pPCI) with drug-eluting stents (DES) has emerged as the standard of care, but stent-related events have persisted. Drug-coated balloon (DCB)–only angioplasty is an emerging technology, although it is not fully evaluated compared with DES in the context of pPCI. Objectives: The aim of this study was to investigate the safety of DCB-only angioplasty compared with second-generation DES in pPCI. Methods: All-cause mortality and net adverse cardiac events (cardiovascular mortality, acute coronary syndrome, ischemic stroke or transient ischemic attack, major bleeding, and unplanned target lesion revascularization [TLR]) were compared among all patients treated with DCBs only or with second-generation DES only for first presentation of ST-segment elevation myocardial infarction (STEMI) due to de novo disease between January 1, 2016, and November 15, 2019. Patients treated with both DCBs and DES were excluded. Data were analyzed using Cox regression models, Kaplan-Meier estimator plots and propensity score matching. Results: Among 1,139 patients with STEMI due to de novo disease, 452 were treated with DCBs and 687 with DES. After a median follow-up period of >3 years, all-cause mortality was 49 of 452 and 62 of 687 in the DCB and DES groups, respectively (P = 0.18). On multivariable Cox regression analysis, there was no difference in mortality between DCBs and DES in the full and propensity score–matched cohorts. Age, frailty risk, history of heart failure, and family history of ischemic heart disease remained significant independent predictors of mortality. There was no difference in any of the secondary endpoints, including unplanned TLR. Conclusions: DCB-only angioplasty appears safe compared with DES for STEMI in terms of all-cause mortality and all net adverse cardiac events, including unplanned TLR. DCB may be an efficacious and safe alternative to DES in selected patient groups. (Drug Coated Balloon Only vs Drug Eluting Stent Angioplasty; NCT04482972)

Download activity - last month

Export as XMLJSONCSV

Download activity - last 12 months

Export as XMLJSONCSV

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item